Edison Investment Research - EMED Mining (EMED) Update: Production in late 2015-early 2016

Report

Edison Investment Research

Update: Production in late 2015-early 2016

Following successful completion of the permitting process at the Rio Tinto project, EMEDâ€™s focus now shifts to securing a funding package. While we have little doubt that the company will be able to raise the required funds, we note considerable progress on refurbishing the project using available equity and debt financing. We value the Rio Tinto copper project at US$262m on an NPV10 using a copper price of US$2.75/lb. Trading on a fully-funded steady-state EV/EBITDA of 3.5x, the stock looks attractive.

11/03/2015 10 EN

Underlying

EMED Mining

See profile

Cyprus

Provider

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

See profile

Other Reports on these Companies

Edison Investment Research

Update: Commercial production by January 2016

The Riotinto copper project achieved first concentrate production on 31 July and following a commissioning phase is expected to start commercial production in January 2016. EMED is on track to complete Phase 1 expansion to 7.5Mtpa by mid-2016 and contemplates a further upgrade to a 9.5Mtpa throughput by the end of 2016. Having updated our copper price assumptions, we revise our valuation of the company to US$326m, or 6.0p/share, using a 10% discount rate. Based on our estimates, the stock trades at an undemanding 2016e EV/EBITDA of c 4.0x.

September 16, 2015 September 16, 2015 6 EN

Edison Investment Research

Update: Equity offering to fully fund the Rio Tinto project

EMED has completed an equity offering to fully fund the development of the Rio Tinto copper project to 7.5Mtpa and pay down debt. Following the placement, four strategic investors control 72.5% of the company. With Phase I construction 80% complete, first production is expected in H215, 5.0Mtpa capacity in Q116 and 7.5Mtpa run-rate by mid-2016. We update our valuation of the company to US$353m, or 6.5p/share on a funded basis, using a conservative long-term copper price assumption of US$2.75/lb. On our estimates, EMED trades at an attractive 2016e EV/EBITDA of 3.1x.

July 14, 2015 July 14, 2015 10 EN

Basilea Pharmaceutica - Cresemba milestone payments continue to roll in

Basilea Pharmaceutica has announced the triggering of a US$1.25m milestone payment from Pfizer, triggered by sustained strong sales of Cresemba in the Asia-Pacific region and China. This is the second FY24 milestone payment for the region and is incremental to the payment received in March. We note that, according to the latest available data, total in-market sales of Cresemba amounted to US$473m in the 12 months ending December 2023, representing a +26% year-on-year increase. Basilea is preparing to launch its Phase III programme for fosmanogepix, a broad-spectrum antifungal therapy, with the...

May 17, 2024 May 17, 2024 1 EN

Toby Thorrington

Toby Thorrington

AAC Clyde Space - Solid start to the year with further order growth

AAC Clyde Space offers exposure to the fast-growing low Earth orbit space market. A solid start to the year and continued order momentum are encouraging. We also note the internal restructuring to promote delivery of the group’s products and services. We expect this combination to drive an improving performance, albeit within the lumpy nature of the business, in turn improving investor confidence and the stock’s valuation.

May 17, 2024 May 17, 2024 1 EN

Richard Williamson

Richard Williamson

Tinexta - Typical seasonality in Q124

Tinexta’s Q124 results showed good progress in the two divisions that typically demonstrate more consistent (through the year) growth, Cyber Security and Digital Trust, which management expects to deliver higher growth over the next few years. Business Innovation demonstrated its typical seasonality and management therefore remains confident about the outlook for the year.

May 17, 2024 May 17, 2024 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Update: Production in late 2015-early 2016

Update: Commercial production by January 2016

Update: Equity offering to fully fund the Rio Tinto project

Basilea Pharmaceutica - Cresemba milestone payments continue to roll in

AAC Clyde Space - Solid start to the year with further order growth

Tinexta - Typical seasonality in Q124

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe